<SEC-DOCUMENT>0001213900-25-072838.txt : 20250807
<SEC-HEADER>0001213900-25-072838.hdr.sgml : 20250807
<ACCEPTANCE-DATETIME>20250807084422
ACCESSION NUMBER:		0001213900-25-072838
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250807
DATE AS OF CHANGE:		20250807

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			China SXT Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001723980
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			D8
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-90926
		FILM NUMBER:		251191841

	BUSINESS ADDRESS:	
		STREET 1:		178 TAIDONG ROAD NORTH
		CITY:			TAIZHOU
		STATE:			F4
		ZIP:			225300
		BUSINESS PHONE:		8652386298290

	MAIL ADDRESS:	
		STREET 1:		178 TAIDONG ROAD NORTH
		CITY:			TAIZHOU
		STATE:			F4
		ZIP:			225300

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TAN SOO SENG
		CENTRAL INDEX KEY:			0002078261
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		BLK 264 JURONG EAST STREET 24 #12-521
		CITY:			SINGAPORE
		PROVINCE COUNTRY:   	U0
		ZIP:			600264
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13G</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: TAN SOO SENG -->
          <cik>0002078261</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <securitiesClassTitle>Ordinary shares, $0.51 per Ordinary Share and associated Warrants</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>07/29/2025</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001723980</issuerCik>
        <issuerName>China SXT Pharmaceuticals, Inc.</issuerName>
        <issuerCusip>G2161P157</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>178 TAIDONG ROAD NORTH</com:street1>
          <com:city>TAIZHOU</com:city>
          <com:stateOrCountry>F4</com:stateOrCountry>
          <com:zipCode>225300</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>TAN SOO SENG</reportingPersonName>
      <citizenshipOrOrganization>U0</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>10392160.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>10392160.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>10392160.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>8.95</classPercent>
      <typeOfReportingPerson>IN</typeOfReportingPerson>
      <comments>Percentage of class is calculated based on 116,027,758 Ordinary Shares outstanding as of July 29, 2025, which information was provided by the Issuer to the Reporting Person on July 29, 2025. Given that as of July 29, 2025, the Issuer has 116,027,758 Ordinary Shares outstanding, comprising 116,027,226 Class A Ordinary Shares, each entitled to one vote, and 532 Class B Ordinary Shares, each entitled to fifty votes, the total voting power of the Issuer is 116,053,826 votes. The Reporting Person holds 10,392,160 Class A Ordinary Shares, representing approximately 8.95% of the total voting power of the Issuer.</comments>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>China SXT Pharmaceuticals, Inc.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>178 TAIDONG ROAD NORTH, TAIZHOU F4 225300</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>TAN SOO SENG</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>Blk 264 Jurong East Street 24 #12-521 Singapore 600264</principalBusinessOfficeOrResidenceAddress>
        <citizenship>SINGAPORE/U0</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>Y</notApplicableFlag>
      </item3>
      <item4>
        <amountBeneficiallyOwned>10,392,160</amountBeneficiallyOwned>
        <classPercent>8.95%</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>10,392,160</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>0</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>10,392,160</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>0</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>N</notApplicableFlag>
        <classOwnership5PercentOrLess>Y</classOwnership5PercentOrLess>
      </item5>
      <item6>
        <notApplicableFlag>Y</notApplicableFlag>
      </item6>
      <item7>
        <notApplicableFlag>Y</notApplicableFlag>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>
      </item10>
    </items>
    <signatureInformation>
      <reportingPersonName>TAN SOO SENG</reportingPersonName>
      <signatureDetails>
        <signature>/s/ TAN SOO SENG</signature>
        <title>TAN SOO SENG</title>
        <date>08/07/2025</date>
      </signatureDetails>
    </signatureInformation>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
